Mode
Text Size
Log in / Sign up
N/A N=30 Randomized Single-blind Treatment

Safety and Efficacy Study of Polydioxanone (PDS) Plates in Rhinoplasty

Rhinoplasty

Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Nov 2020
Primary outcome: Primary: Live Assessment of Satisfaction With the Grafts — 2; 4 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Polydioxanone (PDS) plates (Device); Caudal septal extension graft performed through endonasal rhinoplasty (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
DeNova Research
Primary completion
Jan 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Live Assessment of Satisfaction With the Grafts
2; 4
PRIMARY
Assessment of Tip Projection
0.55; 0.58; 0.54; 0.58; 0.54; 0.57
PRIMARY
Non-treating Blinded Evaluator Satisfaction Assessment
2; 2
PRIMARY
Ease of Use
17; 46.4
SECONDARY
Number of Participants With Infection, Rejection, and Extrusion of the Graft at 1 Week, 1 Month, 3 Months, 6 Months, and 12 Months
0; 1; 0; 0; 0; 0
SECONDARY
Intraoperative Duration
604.7; 571.5

Summary

The purpose of this study is to determine efficacy, safety, and ease of cartilaginous grafting using polydioxanone (PDS) plates in comparison to non-plated cartilaginous grafts as performed through an endonasal rhinoplasty approach in patients requiring a caudal septal extension (CSE) graft.

Eligibility Criteria

Inclusion Criteria

  • Males and females between 18 and 65 years of age.
  • Subjects requesting primary or secondary rhinoplasty and requiring a CSE graft performed through an endonasal approach.
  • Subjects willing to undergo PDS plating.
  • Subjects with either ear conchal or septal cartilage available for grafting purposes.
  • Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.
  • Willingness and ability to comply with the PI's standard preoperative and postoperative rhinoplasty instructions.
  • Subjects of childbearing potential must have a negative urine pregnancy test result at Visit 1 and be willing able to use an acceptable method of birth control (e.g., barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following is documented on the medical history:
  • postmenopausal for at least 12 months prior to study drug administration
  • without a uterus and/or both ovaries
  • has had a bilateral tubal ligation for at least 6 months prior to study drug administration.
  • absence of an other physical condition according to the PI's discretion
  • Willingness and ability to provide written photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup).
  • Willingness and ability to provide written informed consent prior to performance of any study related procedure.

Exclusion Criteria

  • Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.
  • Subjects with a significant systemic illness or illness localized to the areas of treatment.
  • Subjects with previous history of nasal implants.
  • Subjects with previous or current history of nasal infections.
  • Subjects who have history of blood thinners (aspirin, ibuprofen, naprosyn, herbal supplements, Vitamin E) within the two weeks prior to surgery.
  • Subjects who have smoked within the two weeks prior to surgery.
  • Subjects who have had alcohol or illicit drugs one week prior to surgery.
  • Subjects who have eaten or drank anything after midnight the night prior to surgery.
  • Subjects with current history of chronic drug or alcohol abuse.
  • History of autoimmune disease.
  • Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication.
  • Subjects who anticipate the need for surgery, other than the study procedure, or overnight hospitalization during the study.
  • Subjects who, in the Investigator's opinion, have a history of poor cooperation, non compliance with medical treatment or unreliability.
  • Enrollment in any active study involving the use of investigational devices or drugs.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01225250). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search